Modalis Therapeutics

Company Type: Therapeutic development

Main focus: Developing novel gene therapies for rare diseases through modulation of the epigenome

Company stage: Pre-clinical

Diseases: Muscular disorders, diseases of the central nervous system and cardiovascular disease

Genome-editing tool: CRISPR-GNDM®

Funding stage: Series B

Location: Chuo-ku, Tokyo, Japan

Website: https://www.modalistx.com/en/

Pipeline: https://www.modalistx.com/en/business/pipeline/

Partners:

Modalis Therapeutics is a pre-clinical stage biotech company based in Japan, with operations in Massachusetts, focused on developing novel gene therapeutics through its proprietary CRISPR-GNDM® technology. CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) involves precise modulation of gene expression through epigenetic targeting. The company’s pipeline includes several pre-clinical gene therapy candidates to treat muscular disorders, cardiovascular disease, and central nervous system disease.